drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, gene-modified CD19-directed CAR T-cell therapy with metabolic armoring designed to enhance T-cell metabolic fitness, expansion, persistence, and function in the tumor microenvironment; mediates CD19-specific cytotoxicity against B-cell lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor. Binding to CD19 on B-cell lymphomas activates the T cells to proliferate, release cytokines, and kill target cells via perforin/granzyme. Metabolic armoring enhances T-cell metabolic fitness, expansion, and persistence in the tumor microenvironment to improve anti-tumor activity.
drug_name
Meta10-19 (Metabolically Armed CD19 CAR-T cells)
nct_id_drug_ref
NCT06120166